Last reviewed · How we verify
FOSLEVODOPA
Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease.
FOSLEVODOPA, marketed by AbbVie GK, is a levodopa prodrug designed to address motor fluctuations in advanced Parkinson’s disease patients. Its key strength lies in its mechanism of increasing brain levodopa levels, potentially offering more stable symptom control compared to standard levodopa. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | FOSLEVODOPA |
|---|---|
| Sponsor | AbbVie GK |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2024 |
Mechanism of action
Think of it like a delivery system for a medication that's already available in the body. Foslevodopa helps to get more of this medication to the brain, where it's needed to help control movement and other symptoms of Parkinson's disease. This can help to improve a person's quality of life and reduce the severity of their symptoms.
Approved indications
- Motor fluctuations in advanced Parkinson’s disease
Common side effects
Drug interactions
- Selective MAO-B inhibitors (e.g., rasagiline, selegiline)
- Antihypertensive drugs
- Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide, papaverine)
- Isoniazid
- Nonselective MAO inhibitors (e.g., phenelzine, tranylcypromine)
Key clinical trials
- A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa
- Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting
- Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
- Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
- A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
- Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
- Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
- Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOSLEVODOPA CI brief — competitive landscape report
- FOSLEVODOPA updates RSS · CI watch RSS
- AbbVie GK portfolio CI